GO
Loading...

Enter multiple symbols separated by commas

AstraZeneca PLC

More

  • June 2- AstraZeneca Plc would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body's immune response, Bloomberg quoted Chief Executive Pascal Soriot as saying on Tuesday. An earlier version of the Bloomberg article quoted Soriot as saying that AstraZeneca would consider buying a company such as Juno Therapeutics...

  • *Dollar drops on optimism of Greece deal with creditors. *Intel drops after rating cut; biggest drag on indexes. June 2- U.S. stocks erased earlier losses to turned positive on Tuesday afternoon on optimism that Greece would strike a deal with its creditors, while weak U.S. data and bearish comments from a Federal Reserve board member allayed fears of a near-term...

  • *Juno jumps on report of AstraZeneca interest. June 2- U.S. stocks were lower in late morning trading, paring some of their losses earlier in the session, as weak factory orders data and bearish comments from a Federal Reserve board member allayed fears of a rate hike coming sooner rather than later. "Interest rates are not going to matter if they're rising because of...

  • June 2- AstraZeneca Plc would consider buying a company such as Juno Therapeutics Inc, Bloomberg reported AstraZeneca's CEO as saying, according to StreetInsider. AstraZeneca and Juno already have a collaboration agreement to test one of AstraZeneca's cancer drugs in combination with Juno's CAR-T cell therapy, which is considered to be a breakthrough in...

  • June 2- AstraZeneca Plc would consider buying a company such as Juno Therapeutics Inc, Bloomberg reported AstraZeneca's CEO as saying, according to StreetInsider. The companies were not immediately available to comment. Juno is one among the few companies that are developing a new class of immuno-oncology treatments called CAR-T cell therapies.

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...

  • The National Cancer Institute's NCI-MATCH trial will be a massive precision medicine experiment at more than 2,400 sites around the country. Douglas Lowy, the Cancer Institute's acting director. Details of the study were revealed Monday at an American Society of Clinical Oncology conference in Chicago.

  • *Roche, AstraZeneca gain on positive updates. LONDON, June 1- European shares held steady at the start of the month on Monday, with a rally in some drug stocks on the back of positive company updates offset by lingering concerns over Greece's debt situation and weaker commodity stocks. Drugmakers Roche and AstraZeneca, up 2.2 percent and 1 percent respectively,...

  • LONDON, June 1- European shares kicked off June on a positive note on Monday, helped by a rise in pharma stocks, although main indexes were still stuck in their recent range as uncertainty persisted over Greece's future. Athens and its euro zone and International Monetary Fund creditors have been locked in talks for months on a cash-for-reforms agreement.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • New class of drugs shows promise for cancer fight Friday, 29 May 2015 | 2:18 PM ET

    A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.

  • Teva to pay $1.2 billion in drug-delay settlement Thursday, 28 May 2015 | 11:07 AM ET

    WASHINGTON— Federal regulators announced Thursday that Teva Pharmaceuticals Industries will pay $1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil. But Federal Trade Commission officials have argued for over a decade that the agreements keep...

  • COPENHAGEN, May 26- Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Boosting the immune system is now a top priority for cancer drug companies such as Bristol-Myers, Merck, Roche and AstraZeneca, fuelling renewed...

  • Early movers: TWC, AAPL, CTRP, CRM, GM & more Tuesday, 26 May 2015 | 7:54 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, May 26- AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial...

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen said.

  • Amgen ends work on experimental psoriasis drug Friday, 22 May 2015 | 5:27 PM ET

    NEW YORK— Drugmakers Amgen and AstraZeneca said Friday that some patients who took an experimental psoriasis drug experienced suicidal thoughts or behavior, and Amgen said it is ending development of the drug. Amgen was in charge of studying brodalumab, a potential treatment for moderate to severe plaque psoriasis and two other inflammatory diseases,...

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen...

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen...

  • May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization. The FDA said its Adverse Event Reporting System database...